share_log

Pasithea Stock Plunges After Equity Raise of $30M

Pasithea Stock Plunges After Equity Raise of $30M

Pasithea股票在股权融资3000万美元后暴跌
Benzinga Real-time News ·  2021/11/24 13:00

Pasithea Therapeutics Corp (NASDAQ:KTTA) shares shed their gains from yesterday after it announced a private offering of 8.68 million shares and warrants to purchase 8.68 million shares.

帕西娅治疗公司纳斯达克(KTTA)股价昨日下跌，此前该公司宣布私募868万股和认股权证，购买868万股。

  • The offer price of $3.50 per share represents a steep discount of 38% from the last close price of $5.60 that more than doubled on Tuesday.
  • Related Link: EXCLUSIVE: Pasithea's Depression Treatment, Esketamine Nasal Spray Added In Clinic Offerings In UK.
  • The gross proceeds are expected to be approximately $30.4 million.
  • The warrants will be immediately exercisable and have an exercise price of $3.50 per share. 
  • The warrants will expire five years from the date of issuance. 
  • The offering is expected to close by November 29.
  • Pasithea will use the proceeds to fund pre-clinical research and development work for future product candidates, invest in developing the US and the UK clinic businesses, and for working capital and general corporate purposes.
  • Price Action: KTTA shares are down 26.1% at $4.14 during the market session on the last check Wednesday.
  • 收购价为每股3.50美元，较周二上涨逾一倍的上一交易日收盘价5.60美元大幅折让38%。
  • 相关链接： 独家报道：Pasithea的抑郁症治疗，英国临床产品中增加了埃斯氯胺酮鼻腔喷雾剂.
  • 预计总收益约为3040万美元。
  • 认股权证将立即可行使，行权价为每股3.50美元。
  • 权证将自发行之日起五年到期。
  • 此次发行预计将于11月29日完成。
  • Pasithea将利用所得资金为未来候选产品的临床前研究和开发工作提供资金，投资于发展美国和英国的诊所业务，并用于营运资本和一般企业用途。
  • 价格行动：周三尾盘，KTTA股价下跌26.1%，至4.14美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发